The sinonasal mucosa is the first epithelial surface encountered by inhaled microbes and allergens.
1 B cells and their immunoglobulins play an active role in surveillance of this mucosal barrier and protection against infectious diseases.
2,3
B cells can directly recognize and respond to pathogens through their surface-bound immunoglobulins (also known as the B-cell receptor), and they help other immune effector cells recognize and respond to pathogens through secretion of antibodies that interact with Fc receptors expressed on immune effector cells. 4 In addition, B cells play important roles in T H cell activation and can produce a variety of cytokines and effector molecules that can contribute to the host response against pathogens. However, when B-cell responses are not properly regulated, they can lead to disease.
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the nose and sinuses that persists for at least 12 weeks and affects up to 12% of the population in Europe and the United States. 5 CRS is often divided into 2 subtypes, chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP), based on clinical findings. Patients with CRSwNP generally have more severe radiographic disease and a greater propensity for recurrence after sinus surgery but make up a smaller proportion of all patients with CRS.
Abbreviations used
BAFF: B-cell activating factor of the TNF family BAFF-R: B-cell activating factor of the TNF family receptor CRS: Chronic rhinosinusitis CRSsNP: Chronic rhinosinusitis without nasal polyps CRSwNP: Chronic rhinosinusitis with nasal polyps CVID: Common variable immunodeficiency EBI2: EBV-induced protein 2 GC: Germinal center GPA: Granulomatous polyangiitis ICOS: Inducible costimulator NF-kB: Nuclear factor kB sIgA: Selective IgA SLO: Secondary lymphoid organ TACI: Transmembrane activator and calcium modulator and cyclophilin ligand interactor TLO: Tertiary lymphoid organ a variety of inflammatory endotypes. [7] [8] [9] CRS is a complex disease that is likely driven by multiple environmental, genetic, and inflammatory mechanisms, and many recent studies indicate that B cells can play a critical role in the pathogenesis of this disease. 10 This review will highlight recent evidence that supports a role for B cells and antibodies in the pathogenesis of CRS.
B CELLS AND ANTIBODIES IN THE UPPER AIRWAYS AND SINUSES B-cell activation in the mucosa
B cells are thought classically to recognize their cognate antigen and become activated in secondary lymphoid organs (SLOs) through the germinal center (GC) reaction. After they leave the SLOs, activated B cells can then traffic to sites of inflammation and participate in inflammatory responses. The details of these classic B-cell activation mechanisms have been covered extensively elsewhere and are beyond the scope of this review. 11 Importantly, B cells can also be activated directly at sites of inflammation, including the airways. 10 Mucosal-associated lymphoid tissues have been well characterized, especially Peyer patches in the gut and the Waldeyer ring (eg, tonsils and adenoids) in the airways.
Rabbits and rats also have constitutive bronchus-associated lymphoid tissue and nasal-associated lymphoid tissue, but these tertiary lymphoid organs (TLOs) are largely absent in healthy murine and human airways. 12 However, the formation of TLOs can be induced in the airways by inflammation, and inducible bronchus-associated lymphoid tissue has been shown to be critical for the optimal response to and clearance of pathogens and even tumors in human subjects. 13, 14 The structures of follicles within TLOs are similar to those found in SLOs, although they tend to be less well organized. 10 Because of this lack of organization and possibly reduction in clonal selection (see below), it has been speculated that TLOs might allow for activation of autoreactive B-and T-cell clones, which could contribute to chronic inflammation or development of autoimmunity. 15, 16 Although TLOs in the airways are associated with protective immune responses, their presence is also associated with chronic inflammatory diseases, including asthma and COPD, as well as autoimmiunity. 12 
B cells in patients with CRS
Although B cells and plasma cells have been described in the inflammatory infiltrate in patients with CRS, 17 the specificity and pathogenic potential of these B cells remained underexplored until recently. Early immunohistologic studies demonstrated increased expression of the B-cell marker CD19 and the plasma cell marker CD138 in tissue from patients with CRSwNP, 18 which GLOSSARY ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCAs): Autoantibodies specific for different enzymes contained within primary granules of neutrophils and macrophages. c-ANCA and p-ANCA refer to the patterns seen on immunofluorescences studies (cytoplasmic and perinuclear, respectively). The c-ANCA pattern is usually caused by antibodies to serine proteinase 3 and is found in patients with granulomatosis with polyangiitis. The p-ANCA pattern is typically caused by antibodies to myeloperoxidase.
CD180: Also known as RP105, a cell-surface molecule that associates with MD-1 to form a complex that functions as a Toll-like receptor that recognizes LPS from gram-negative bacteria. 
FOLLICULAR DENDRITIC CELLS:

IL-21:
The signature cytokine of follicular T H cells. IL-21 is required for germinal center development. IL-21 also induces B-cell apoptosis that is only averted if the B cell is rescued by high-affinity receptors for antigen.
INCOMPLETE PENETRANCE:
In complete penetrance everyone with a pathogenic genotype expresses the disease. In incomplete penetrance only some will express the disease, indicating other genetic or environmental factors must be present. Penetrance represents the probability of disease when a pathogenic genotype is present. One of the more common clinical examples of penetrance variability is seen in women with breast cancer susceptibility mutations of the BRCA genes: both mutations and other factors, such as family history and ethnicity, determine disease probability. The Editors wish to acknowledge Daniel Searing, MD, for preparing this glossary.
were later confirmed to represent increased numbers of B cells and plasma cells, respectively, based on flow cytometry. 19 On histopathologic examination, organization of the B-cell infiltrates into clusters has been reported in patients with CRS, 20, 21 but the infrequency of these clusters and the rarity with which they are organized into GCs put their significance in doubt.
Our own systematic quantitative histopathologic study of sinus tissues from patients with CRSwNP and control subjects found that TLOs were present in nasal polyp tissue but were not increased in frequency compared with those in non-CRS control uncinate tissue when normalized to tissue volume. 22 However, a recent report by Lau et al 23 found that 37% of tissue from patients with recalcitrant CRSwNP had evidence for the formation of TLOs in their nasal polyps based on identification of lymphoid clusters with peripheral lymph node addressin and follicular dendritic cells, whereas none of the tissues from control subjects contained such structures. Although it is clear that B-lineage cells play important roles in CRS pathogenesis, the question of whether TLOs play an important role in activation of B cells and antibody production in nasal polyps, whether these events occur in extrafollicular locations, and whether the appearance of TLOs varies in the disease state in patients from distinct geographic regions will require more study (Fig 1) .
Recent studies have evaluated the phenotype of B cells within the nasal mucosa of patients with CRS to discover mechanisms by which these B cells can be activated. Studies from our group have used B cells from adult tonsillar tissue to serve as a control for classically activated B cells to compare with the phenotypes of B cells in nasal polyps. We have found that although total CD19 1 naive and GC B cells were less frequent in nasal polyps, numbers of CD19 1
CD27
1 CD38 hi plasmablasts were increased dramatically in nasal polyps. 22 Interestingly, plasmablasts in nasal polyps also had a greater frequency of expression of EBV-induced protein 2 (EBI2) compared with plasmablasts from tonsils. 22 EBI2 is a chemotactic receptor that guides B cells away from GCs to the extrafollicular regions outside the GC in SLOs, 24 suggesting that some B cells in nasal polyps can be activated through an extrafollicular mechanism. We also found that EBI2 expression by B cells could be upregulated by means of coculture of B cells with type 2 innate lymphoid cells. Because numbers of type 2 innate lymphoid cells are highly increased in nasal polyp tissue, 25, 26 this observation provides a possible alternate novel pathway for local B-cell activation in polyp tissue. 22 Another recent report found that numbers of B cells expressing CD180, an unconventional member of the Toll-like receptor family that plays an important role in B-cell activation and proliferation, are also increased in nasal polyps compared with those in control sinus tissue. 27 This suggests that some B cells in nasal polyps can be activated through exposure to pathogen-associated molecular patterns (PAMPs), such as LPS, that can be abundant in the nasal polyp microenvironment.
Although most studies of B cells in patients with CRS have focused on CRSwNP, 2 recent studies have characterized a unique subset of IgD 1
CD19
1 CD38 1 plasmablasts that are increased in both patients with CRSwNP and those with CRSsNP, indicating that B cells might also be important for the pathogenesis of CRSsNP. 28, 29 In related studies IL-21 and T follicular helper-like cells, which are known to secrete IL-21, were found to be increased in the tissue of patients with CRSwNP. 30, 31 T follicular helper cells are well established to play a key role in the activation of B cells in GCs. Taken together, these studies suggest that activation of mucosal B cells in nasal polyps likely occurs through multiple mechanisms, including canonical GC-like reactions and less regulated extrafollicular responses (Fig 1) .
B-cell function in patients with CRS
In addition to expanding understanding of the phenotypes of activated B cells present in tissues from patients with CRS, it is also important to determine the role these cells might play in disease pathogenesis. A recent study has evaluated the antibody secretion potential of B cells from tissue of patients with CRSwNP by using ELISpot and ex vivo cultures and found that nasal polyp-derived B cells more frequently and abundantly secrete IgG, IgA, and IgE compared with tonsillar B cells. 22 These findings are supported by evidence of accumulation of antibodies of every isotype, except IgD, in nasal polyp tissue. 19, 32, 33 Although the highest total levels of antibodies are usually found in patients with CRSwNP, tissue IgD levels were highest in a subpopulation of patients with CRSsNP. 34 There is also accumulating evidence that B cells are activated locally within nasal polyps to secrete antibodies (Fig 1) . Increased expression levels of germline transcripts for IgG, IgA, and IgE have been reported in nasal polyp tissues. 22, 32 Germline transcripts are expressed very briefly during class-switch recombination and serve as markers of cells actively undergoing this process. 35 In addition, expression of activation-induced cytidine deaminase and the recombination-activating gene proteins, both of which are required for generation of antibody diversity and class-switch recombination, are increased in nasal polyps. 22, 32 Although the antigen specificity of the antibodies in nasal polyps remains largely unknown, there is evidence that some of the antibodies are autoreactive (see below), 36, 37 and some of them, especially among the IgE antibodies, are specific for enterotoxins from Staphylococcus aureus. 38, 39 Interestingly, the presence of either local or systemic IgE to S aureus and its enterotoxins can serve as a biomarker for more severe disease. 9, 40 Moreover, nasal polyp-localized polyclonal IgE appears to be functional because it induces histamine release from tissue extracts exposed to antigens. 41 Another potential mechanism for local activation of B cells in patients with CRSwNP is overexpression of B cell-activating factor of the TNF family (BAFF), which plays a critical role in B-cell activation and differentiation to plasma cells. 1, 42 Likewise, the type 2 cytokines IL-5 and IL-13 are overexpressed in nasal polyp tissue, 43 and each are capable of activating B cells or promoting class-switching. 44, 45 Overall, it is clear that activated B cells accumulate in the sinus tissues of patients with CRS, and many of these B cells produce large amounts of antibodies.
B-CELL IMMUNODEFICIENCIES: WHAT HAPPENS WHEN NORMAL B-CELL RESPONSES ARE LOST? Antibody defects associated with sinus and/or airway symptoms
Overproduction of antibodies can lead to inflammation and disease through activation of complement and/or innate effector immune cells that express Fc receptors. However, decreased antibody production can also lead to disease because of inadequate protective humoral immune responses against microbes (Fig 1, left) . Interestingly, antibody deficiencies are the most common immunodeficiencies in patients with rhinosinusitis. Diseases associated with antibody deficiencies have very heterogeneous clinical presentations, and their exact pathogenesis is not known. The 3 best-described antibody immunodeficiencies are selective IgA (sIgA) deficiency, specific antibody deficiency, and common variable immunodeficiency (CVID). Antibody deficiencies are categorized as mild or severe based on their pathogenesis and levels of antibody production and function.
CVID is the most common symptomatic immunodeficiency in adults and is characterized by low systemic levels of IgG and IgA and/or IgM antibodies. IgG levels in these patients are typically less than 2 SDs below the mean adjusted for age. Antibody function in patients with CVID is also impaired, as supported by a poor response to both polysaccharide-and protein-based vaccines. 46 sIgA deficiency is characterized by serum IgA levels of less than 7 mg/dL, with normal levels of both IgG and IgM antibodies. Antibody responses to polysaccharide vaccines might or might not be normal in patients with sIgA deficiency. 47 Specific antibody deficiency is characterized by normal or low-to-normal levels of quantitative immunoglobulins but a poor response to polysaccharide antigens. 48 In general, disorders with a significant decrease in the quantity of IgG antibodies, like CVID, tend to cause more severe immunodeficiency, whereas IgA deficiency and specific antibody deficiencies tend to be milder.
Patients with symptomatic antibody deficiencies often present with sinopulmonary infections, and thus it is important for health care professionals who treat patients with rhinosinusitis to be aware of these immunodeficiencies. Among patients with difficult-to-treat CRS, a meta-analysis estimated that the prevalence of pooled IgG, IgA, and IgM deficiency was 23%, whereas 8% to 34% of patients had specific antibody deficiency. 49 More recently, in a well-characterized cohort of patients with CRS who were screened for an immunodeficiency, 5% were found to have CVID, and 24% were noted to have a specific antibody deficiency, which is much higher than the estimated rate of 1 in 100,000 to 1 in 10,000 in the general population. 46, 50, 51 Interestingly, patients with CRSsNP were more likely to have CVID and specific antibody deficiency compared with patients with CRSwNP. We can speculate that this might explain some of the differences seen in activated B cells and increased antibody levels in tissue from patients with CRSwNP compared with tissue from patients with CRSsNP.
Mechanisms of B-cell immunodeficiencies
B-cell dysfunction underlies the pathogenesis of antibody deficiencies, although defects in other innate and adaptive immune cells, such as T cells and natural killer cells, have also been described. 52 Characteristic B-cell defects in patients with antibody deficiencies involve reduced B-cell survival, defective isotype switching, and/or decreased numbers of switched memory B cells. 53, 54 More rarely, peripheral B-cells numbers can be low. 55 Defects in the polymeric immunoglobulin receptor, which transports IgA and IgM across the epithelium, can also lead to insufficient levels of these protective antibodies on the mucosal surface. 56 Genetic defects have been linked to about 10% of patients with CVID and IgA deficiency. Mutations in the inducible costimulator (ICOS) gene were among the first defects described in patients with CVID. 57 ICOS is important in B-cell activation and generation of memory B cells and plasma cells. Accordingly, mutations in ICOS result in decreased production of antibodies and reduced numbers of memory and switched memory B cells. 58 Additional defects reported in patients with CVID include mutations of the proteins in the B-cell coreceptor complex (CD21-CD19-CD81).
59-61 CD19 functions with CD21 and CD81 to enhance signaling from the B-cell receptor. Defects in these receptors are associated with hypogammaglobulinemia, decreased memory B-cell numbers, and impaired specific antibody responses. 59, 62 Further B-cell dysfunction in patients with CVID results from mutations in the receptors for BAFF: B-cell activating factor of the TNF family receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). [63] [64] [65] [66] [67] BAFF and the related cytokine, a proliferation-inducing ligand, are important for B-cell survival, proliferation, and T cell-independent class-switch recombination. 68, 69 Defects in these receptors lead to hypogammaglobulinemia and associated clinical manifestations of antibody deficiencies. TACI mutations have also been reported in sIgA deficiency. 64, 65 These mutations in patients with sIgA deficiency eventually lead to defects in the differentiation of IgA 1 B cells to IgA-secreting plasma cells, which results in reduced IgA production. 70 B-cell maturation to antibody-secreting plasma cells, antibody isotype switching, and development of switched memory B cells are dependent on downstream activation of the canonical and noncanonical nuclear factor kB (NF-kB) pathways through the B-cell receptor complex, BAFF-R, and TACI. Mutations in the NF-kB2 (noncanonical) and NF-kB1 (canonical) pathways have been reported in patients with CVID. NF-kB1 mutations have also been described in patients with IgA deficiency. 71 Interestingly, BAFF-R, TACI, and NF-kB mutations are noted in relatives of patients with CVID who do not have the abnormal clinical features typical of antibody deficiencies. 67, 72 It has been speculated that the disease manifestations can appear later in life in these patients or that there might be incomplete penetrance of these mutations.
Similar to CVID and sIgA deficiency, specific antibody deficiency has been associated with a low percentage of CD19
IgD
2 switched memory B cells compared with control values. 73, 74 Alachkar et al 73 have also reported that the reduced frequency of switched memory B cells was associated with a significantly higher prevalence of bronchiectasis and autoimmunity in patients with humoral immunodeficiency, including CVID and specific antibody deficiency.
Overall, antibody deficiency should be considered in patients presenting with persistent CRS. Underlying genetic mutations have been identified in about 10% of patients with primary antibody immunodeficiencies, as mentioned above. In general, many of the known genetic mutations in primary antibody deficiencies affect B-cell survival, isotype switching, B-cell signaling, or transport of immunoglobulins to the mucosal surface (eg, the polymeric immunoglobulin receptor). Although available evidence suggests that increased frequency and intensity of sinonasal infections results from these defects in B-cell responses, how these antibody deficiencies are pathogenic remains unclear in the majority of patients with CRS, and further studies are necessary to elucidate the underlying mechanisms responsible for this common and often disabling disease.
AUTOIMMUNITY: WHAT HAPPENS WHEN B-CELL RESPONSES ARE DIRECTED TOWARD SELF? B-cell manifestations of airway disease
In mice mucosal B-cell responses vary depending on whether the B cells are derived from B1 B cells that undergo maturation outside the bone marrow or B2 B cells that undergo maturation within the bone marrow.
75 B1 B cells are found at high density at mucosal sites, such as the pleural and peritoneal cavities, and can be activated directly without T cells. B2 B cells are concentrated in GCs of lymph nodes but require T-cell help for activation. B1 B cells innately express immunoglobulin sequences that bind microbial motifs but are also autoreactive and polyreactive. B1 B cells are also long-lived and noncirculating. In contrast, because of their history of GC generation, the affinity of mature B2 B-cell antibodies is higher and B2 cell-derived antibodies are less likely to manifest autoreactivity because of clonal selection during development in the bone marrow. Although the question of whether human subjects also have distinct B1 and B2 lineage B cells remains controversial, 76, 77 the canonical characteristics of mucosal B cells in mice might have significant value in interpretation of the nature of B cells isolated from human sinonasal mucosa.
In healthy nasal mucosa, B cells and their derived plasma cells are relatively rare, 19 but dysregulation and expansion of B-cell responses in the nasal mucosa play a pathogenic role in allergic and autoimmune disorders of the upper airway. In patients with allergic rhinitis, uptake, processing, and presentation of allergens by dendritic cells to T cells results in T H 2 priming and ultimately switching of B cells toward production of systemic and local aeroallergen-specific IgE. Mast cells and basophils primed with aeroallergen-specific IgE degranulate when they encounter their cognate aeroallergen and mediate classic allergic symptoms of rhinorrhea and congestion. 78 In contrast, when hypersensitivity becomes targeted against self-antigens, B cells can mediate highly destructive inflammation in the upper airway. For example, anti-neutrophil cytoplasmic antibodies are the primary cause of a spectrum of autoimmune necrotizing vasculitic diseases, including granulomatous polyangiitis (GPA; formerly known as Wegener granulomatosis) and eosinophilic GPA (formerly known as Churg-Strauss syndrome), that have prominent sinonasal and pulmonary manifestations. [79] [80] [81] Although less commonly recognized, other systemic autoimmune conditions, particularly rheumatoid arthritis, can be associated with the development of interstitial lung disease and increased pulmonary ectopic lymphoid tissue, where high-affinity autoreactive B-cell clones are generated. 79, 82 Another airway entity in which B cells play a prominent pathogenic role is IgG 4 -related disease, which is characterized by a lymphoplasmacytic infiltrate enriched in IgG 4 1 plasma cells, as well as CD20
1 B cells and T cells that affect multiple organ sites. 83 Although salivary gland involvement is the most common upper airway manifestation, IgG 4 -related disease can cause symptoms of CRS, and these cells can directly infiltrate sinonasal mucosa, causing fibrolytic lesions in the sinuses. 84 
Evidence for activation of autoreactive B cells in patients with CRS
Although the overall specificity of the antibodies found in patients with CRS has not been systematically characterized, increased mucosal levels of autoreactive IgG and IgA to nuclear antigens, including double-stranded DNA, and basement membrane components have been reported. 36, 37, 85 Interestingly, increased levels of anti-double-stranded DNA IgG were correlated further with local IgE and eosinophilic cationic protein levels and associated with more severe phenotypes of CRSwNP, such as those with aspirin-exacerbated respiratory disease or recurrent nasal polyposis.
To delineate the potential role of complement activation in pathogenicity of the local antibody response, a subsequent study evaluated levels of activated neoepitopes (C1rs-inh, C4d, and C5b-9) of the classical or antibody-mediated complement pathways and found evidence for strong activation of complement in nasal polyp tissue compared with control tissue. 86 Importantly, the complement activation neoepitope C4d is known to bind at the site of activation, and the complement activation appeared to be highly localized to the basement membrane of the nasal polyp epithelium (Fig 1) . Whether this localization is due to activation of complement at the basement membrane by specific anti-basement membrane autoantibodies or specific antibodies against a pathogen localized at the same site remains to be established, but the presence of autoantibodies against basement membrane components would favor the former.
CLINICAL IMPLICATIONS OF B-CELL PATHOGENESIS IN PATIENTS WITH AIRWAY DISEASE
As shown in this review, B-cell responses in the upper airway require careful calibration to balance between insufficient responses, which permit recurrent and/or chronic infections (Fig 1, left) , and unregulated responses, which promote chronic inflammation and/or autoimmunity (Fig 1, right) . From a clinical perspective, these B-cell responses have immediate diagnostic and therapeutic utility, as demonstrated by the clinically beneficial effects of intravenous gammaglobulin and rituximab on sinusitis symptoms seen in patients with CVID and GPA, respectively. 81, 87 Targeting B-cell inflammation in the more common varieties of CRS, in which disease is confined to the upper airways without systemic manifestations, is a focus of current research efforts to identify B cell-based and/or antibody-based biomarkers of disease severity and to validate the utility of such markers for identifying patients with poor treatment outcomes. Furthermore, the increasing availability of safe targeted B-cell therapies can open new avenues for treating patients with B cell-associated inflammation of the paranasal sinuses, although careful selection of the appropriate medication and clinical trials will be needed to demonstrate their efficacy in patients with CRS.
SUMMARY/CONCLUSIONS
B cells and their antibody products play undisputed roles in health and disease within the mucosae of the nose and sinuses. Deficient or inadequate B-cell responses can lead to susceptibility to infectious disease in the nose. Thus, patients with defects in, for example, B-cell activation, expansion, survival, or antibody secretion, often have either chronic or recurrent acute infections, and this can be associated with nonpolypoid CRS. In contrast, many patients with CRSwNP, which is less likely to be driven by pathogens, have excess expression of local immunoglobulins, including autoreactive antibodies. These B-cell responses activate complement in many patients and likely contribute to immunopathogenic responses in the sinonasal mucosae. Finally, CRSwNP in general, whether associated with autoantibodies or not, is characterized by frank expansion of B cells and high levels of local production of IgE and other isotypes of antibodies that can participate in type 2 inflammation. Understanding the molecular and cellular mechanisms of CRS that can be mediated by either inadequate B-cell responses or inappropriate autoimmune B-cell responses should be a high priority in the quest to understand the pathogenesis of the various forms of CRS. 
